Skip to main navigation Skip to search Skip to main content

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer

  • Teodora Radonic
  • , Sepehr Rahmani-Khajouei
  • , for the ETOP Lungscape consortium
  • , Urania Dafni
  • , Albrecht Stenzinger
  • , Martina Haberecker
  • , Line Bille Madsen
  • , Kim Monkhorst
  • , Jacek Kowalski
  • , Javier Hernandez-Losa
  • , Keith M. Kerr
  • , Ernst Jan M. Speel
  • , Lukas Bubendorf
  • , Leena Joseph
  • , Atilio Navarro
  • , Erik Thunnissen
  • , Irene Sansano
  • , Lisa M. Hillen
  • , Wojciech Biernat
  • , Miriam Christoffel
  • Lydia Tsamtsouri, Roswitha Kammler, Solange Peters, Martin Zoche, Rolf A. Stahel*, Stephen P. Finn
*Corresponding author for this work
  • Amsterdam UMC
  • University Hospital Zürich
  • National and Kapodistrian University of Athens
  • University Hospital Heidelberg
  • Aarhus University Hospital
  • Netherlands Cancer Institute
  • Medical University of Gdańsk
  • Hospital Vall d'Hebron & ARADyAL research network
  • NHS Grampian
  • Maastricht University Medical Center +
  • University of Basel
  • Lung Cancer Group Manchester
  • Hospital General Universitario de Valencia
  • Maastricht University
  • ETOP IBCSG Partners Foundation
  • Frontier Science Foundation Hellas
  • University Hospital Lausanne
  • St. James’s Hospital

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: 

Functional NTRK1-2–3 fusions are rare, tumor-agnostic, targetable alterations. Accurate detection is essential to ensure optimal treatment. We investigated the prevalence of NTRK fusions in two cohorts of patients with NSCLC. 

Methods:

The Lungscape Cohort, comprising of tissue microarrays from 1703 resected stage I–III NSCLC cases (52% adenocarcinomas, 40% squamous cell carcinomas), was screened using pan-TRK immunohistochemistry (IHC, EPR17341, Ventana) and positive cases were confirmed by next-generation sequencing (NGS). The NGS Cohort of 24,243 NSCLC was screened by NGS within the European Lungscape Center Network and positive cases were retested using IHC. Functional fusions were defined as in-frame fusions containing an intact NTRK kinase domain. 

Results: 

In the Lungscape Cohort of resected NSCLC panTRK IHC was found positive in 69 (60 squamous cell carcinoma, 5 adenocarcinoma, 4 large cell carcinoma) of 1703 patients (4%, median H-score: 37, range 5–200). Sixty-five samples underwent confirmatory testing by NGS and one fusion was found, which after manual review was classified as non-functional. The NGS Cohort yielded 11 fusions in tumors of 24,243 patients of which eight were functional (0.03%; 5 in NTRK1, 1 in NTRK2 and 2 in NTRK3) and five were retested using IHC (median H score 200, range 50–300). Of the three non-functional fusions, two were IHC negative and 1 weakly positive (H-score 30). 

Conclusion: 

Pan-TRK IHC has a false-positive rate of ∼4%, particularly in squamous cell carcinomas, underscoring the need for confirmatory NGS to validate IHC findings and assess fusion functionality. Functional NTRK1/2/3 fusions remain exceedingly rare in NSCLC, with a detection rate of 0.03% across our combined cohorts.

Original languageEnglish
Article number109514
JournalLung Cancer
Volume218
DOIs
Publication statusPublished - Aug 2026

Bibliographical note

Publisher Copyright:
© 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this